<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="25142">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT02017314</url>
  </required_header>
  <id_info>
    <org_study_id>830458909</org_study_id>
    <nct_id>NCT02017314</nct_id>
  </id_info>
  <brief_title>VAS Correlation With BMI</brief_title>
  <official_title>Correlation of Postoperative VAS Values and Body Mass Index in Patients Undergoing Abdominal Surgery: A Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Istanbul University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Istanbul University</source>
  <oversight_info>
    <authority>Turkey: Ethics Committee</authority>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The aim of the study is to observe if any correlation between Body mass index and VAS values
      exists in patients who has gone under  abdominal surgery.

      Group I : Patients with BMI&lt;30 Group II: Patients with BMI between 30 and 34.9 Group III:
      Patients with BMI between 35 and 39.9 Group IV: Patients with BMI between 40 and 49.9 Group
      V : Patients with BMI &gt;50

      After the end of surgery patients will be extubated and in the recovery room morphine PCA
      (patient-controlled analgesia) treatment will be started according to their adjusted body
      weight. When  VAS values over 4,10 mg/kg Paracetamol IV will be used as an escape treatment.
      VAS values and Delivery and Demand of the PCA and additional need for analgesics will be
      recorded in the first 48 hours.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>November 2013</start_date>
  <completion_date type="Anticipated">March 2014</completion_date>
  <primary_completion_date type="Anticipated">March 2014</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Non-Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Pain Scores on the Visual Analog Scale</measure>
    <time_frame>48 hours</time_frame>
    <safety_issue>No</safety_issue>
    <description>Correlation between the VAS Scores and BMI will evaluated</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Morbid Obesity</condition>
  <arm_group>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with BMI &gt; 50</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with BMI between 40 and 49.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with BMI between 35 and 39.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>patients with BMI between 30 and 34.9</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group I</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients with BMI &lt;30</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Morphine</intervention_name>
    <arm_group_label>Group 5</arm_group_label>
    <arm_group_label>Group IV</arm_group_label>
    <arm_group_label>Group III</arm_group_label>
    <arm_group_label>Group II</arm_group_label>
    <arm_group_label>Group I</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  patients undergoing abdominal surgery and who will be given PCA treatment for
             postoperative pain.

        Exclusion Criteria:

          -  patients younger than 18 years old, patients with uncompensated diabetes or related
             polyneuropathy, patients receiving antidepressants or have a diagnosis of depression
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>60 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>guniz koksal, Ass.Prof</last_name>
    <phone>2124143000</phone>
    <phone_ext>21876</phone_ext>
    <email>gunizkoksal@hotmail.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Cerrahpasa Medical School</name>
      <address>
        <city>Istanbul</city>
        <state>Marmara</state>
        <country>Turkey</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>emre erbabacan, specialist</last_name>
      <phone>00905322067777</phone>
      <email>emreerbabacan@hotmail.com</email>
    </contact>
  </location>
  <location_countries>
    <country>Turkey</country>
  </location_countries>
  <reference>
    <citation>Choi YK, Brolin RE, Wagner BK, Chou S, Etesham S, Pollak P. Efficacy and safety of patient-controlled analgesia for morbidly obese patients following gastric bypass surgery. Obes Surg. 2000 Apr;10(2):154-9.</citation>
    <PMID>10782177</PMID>
  </reference>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 16, 2013</lastchanged_date>
  <firstreceived_date>December 8, 2013</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Istanbul University</investigator_affiliation>
    <investigator_full_name>Guniz M.Koksal</investigator_full_name>
    <investigator_title>Assc.Prof</investigator_title>
  </responsible_party>
  <keyword>morbid obesity</keyword>
  <keyword>postoperative pain</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Obesity</mesh_term>
    <mesh_term>Obesity, Morbid</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Morphine</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
